CALHM5

Across TCGA pan-cancer cohorts, CALHM5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CALHM5 data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CALHM5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CALHM5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where CALHM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.909	0.739	.011	9	view →
PDAC	DFS	Quartile	All	0.635	0.878	.025	7	view →
LSCC	DFS	Tertile	II,III,IV	0.619	0.871	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CALHM5–CCRCC (OS)

Open the CCRCC breakdown →